文献速递胸部肿瘤

PD-L1通过上调BAG-1持续激活ERK信号介导非小细胞肺癌TKI耐药

An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
PubMed 文献 · Eur J Cancer · 2017-09-09

该研究在非小细胞肺癌细胞与动物模型中证实,PD-L1通过ERK信号磷酸化C/EBPβ上调BAG-1转录,BAG-1反过来增加PD-L1表达并持续激活ERK,从而赋予肿瘤侵袭性和酪氨酸激酶抑制剂耐药。作者据此建议,对肿瘤高表达PD-L1且高表达BAG-1的非小细胞肺癌患者,可考虑将ERK抑制剂与TKI联合作为潜在策略。

要点

  • PD-L1通过ERK磷酸化C/EBPβ上调BAG-1转录。
  • BAG-1反向增加PD-L1表达并持续激活ERK信号。
  • PD-L1/BAG-1轴在细胞与动物模型中均介导侵袭和TKI耐药。

核心结论

  • 作者认为,PD-L1通过BAG-1持续激活ERK信号,赋予非小细胞肺癌细胞侵袭性和TKI耐药。
  • 作者建议,对肿瘤高表达PD-L1且高表达BAG-1的非小细胞肺癌患者,可考虑ERK抑制剂联合TKI作为潜在策略。

研究设计与样本

  • 研究为体外非小细胞肺癌细胞实验,并通过动物模型进一步验证机制。
  • 采用聚合酶链反应构建BAG-1启动子及缺失突变体,行荧光素酶报告基因实验。

主要发现

  • PD-L1上调BAG-1转录,由ERK信号磷酸化C/EBPβ负责。
  • PD-L1诱导的BAG-1表达反过来增加PD-L1表达,并因ERK信号持续激活而赋予非小细胞肺癌细胞TKI耐药。
  • 动物模型确认PD-L1/BAG-1轴通过持续激活ERK信号赋予肿瘤侵袭性和TKI耐药。

关键数值与推荐

  • 原文未报告样本量、效应量、置信区间或P值。

临床怎么用

  • 作者建议,对肿瘤高表达PD-L1且高表达BAG-1的非小细胞肺癌患者,可考虑ERK抑制剂联合TKI作为潜在策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High programmed cell death 1 ligand 1 (PD-L1) expression in tumour tissues was associated with poor outcomes in non-small cell lung cancer (NSCLC) due to evasion of tumour immune surveillance. However, the role of PD-L1 in tumour invasion and resistance to tyrosine kinase inhibitor (TKI) treatments is not fully understood. Here, we provide evidence to support the involvement of PD-L1 expression in the invasiveness and TKI resistance in NSCLC cells by increased Bcl-2-associated athanogene-1 (BAG-1) expression. The upregulation of BAG-1 transcription by PD-L1 was verified by constructing the BAG-1 promoters using the polymerase chain reaction (PCR) and deletion mutations for luciferase reporter assays. The results indicated that C/EBPβ phosphorylation by extracellular signal-regulated kinase (ERK) signalling was responsible for PD-L1-mediated BAG-1 transcription. Mechanistically, the PD-L1-induced BAG-1 expression reciprocally increased PD-L1 expression due to persistent activation of ERK signalling, and it consequently conferred TKI resistance in NSCLC cells. The mechanistic action of this cell model was further confirmed by an animal model, affirming that PD-L1 conferred tumour invasiveness and TKI resistance via persistent activation of ERK signalling by the PD-L1/BAG-1 axis. We therefore suggest a combination of an ERK inhibitor with a TKI as a potential strategy for conquering PD-L1-mediated tumour invasion and TKI resistance in NSCLC patients whose tumours harbour high PD-L1/high BAG-1 expression.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lin PL, Wu TC, Wu DW, et al. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling. Eur J Cancer. 2017. PMID: 28892778. doi:10.1016/j.ejca.2017.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。